Current Atherosclerosis Reports

, Volume 14, Issue 1, pp 49–59

Niacin: The Evidence, Clinical Use, and Future Directions

  • Todd C. Villines
  • Andrew S. Kim
  • Rosco S. Gore
  • Allen J. Taylor
Nonstatin Drugs (W Borden, Section Editor)

Abstract

The use of FDA-approved niacin (nicotinic acid or vitamin B3) formulations at therapeutic doses, alone or in combination with statins or other lipid therapies, is safe, improves multiple lipid parameters, and reduces atherosclerosis progression. Niacin is unique as the most potent available lipid therapy to increase high-density lipoprotein (HDL) cholesterol and it significantly reduces lipoprotein(a). Through its action on the GPR109A receptor, niacin may also exert beneficial pleiotropic effects independent of changes in lipid levels, such as improving endothelial function and attenuating vascular inflammation. Studies evaluating the impact of niacin in statin-naïve patients on cardiovascular outcomes, or alone and in combination with statins or other lipid therapies on atherosclerosis progression, have been universally favorable. However, the widespread use of niacin to treat residual lipid abnormalities such as low HDL cholesterol, when used in combination with statins among patients achieving very low (<75 mg/dL) low-density lipoprotein cholesterol levels, is currently not supported by clinical outcome trials.

Keywords

Niacin Nicotinic acid Lipids HDL cholesterol Lipoprotein (a) Apolipoprotein B Statin Atherosclerosis Atherosclerosis imaging Combination lipid therapy Laropiprant 

Reference

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.PubMedCrossRefGoogle Scholar
  2. 2.
    Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48:438–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Hulten E, Jackson JL, Douglas K, et al. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:1814–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.PubMedCrossRefGoogle Scholar
  5. 5.
    Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J. 2008;156:112–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.Google Scholar
  7. 7.
    Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem. 1955;54:558–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–10.PubMedCrossRefGoogle Scholar
  10. 10.
    Jafri H, Alsheikh-Ali AA, Karas RH. Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med. 2010;153:800–8.PubMedGoogle Scholar
  11. 11.
    Wu BJ, Yan L, Charlton F, et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol. 2010;30:968–75.PubMedCrossRefGoogle Scholar
  12. 12.
    Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233–40.PubMedCrossRefGoogle Scholar
  13. 13.
    •• Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis. 2010;210:353–61. This work is a recent meta-analysis that evaluates the impact of niacin, alone or in combination treatment, on all cardiovascular events and atherosclerosis progression from among 11 randomized controlled trials. PubMedCrossRefGoogle Scholar
  14. 14.
    Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264:3013–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Duggal JK, Singh M, Attri N, et al. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease. J Cardiovasc Pharmacol Ther. 2010;15:158–66.PubMedCrossRefGoogle Scholar
  16. 16.
    Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128:262–9.PubMedGoogle Scholar
  17. 17.
    Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110:3512–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22:2243–50.PubMedCrossRefGoogle Scholar
  19. 19.
    •• Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361:2113–22. This work evaluates the comparative efficacy of niacin extended-release versus ezetimibe when added to chronic, stable statin therapy among high-risk patients for the endpoint of change in CIMT over 14 months. PubMedCrossRefGoogle Scholar
  20. 20.
    Thoenes M, Oguchi A, Nagamia S, et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int J Clin Pract. 2007;61:1942–8.PubMedCrossRefGoogle Scholar
  21. 21.
    • Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55:2721–6. This work reports the final results of the ARBITER 6-HALTS trial and investigated the impact of niacin and ezetimibe cumulative drug exposure on change in CIMT. PubMedCrossRefGoogle Scholar
  22. 22.
    Zhao XQ, Krasuski RA, Baer J, et al. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). Am J Cardiol. 2009;104:1457–64.PubMedCrossRefGoogle Scholar
  23. 23.
    Chapman MJ, Redfern JS, McGovern ME, et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126:314–45.PubMedCrossRefGoogle Scholar
  24. 24.
    Gille A, Bodor ET, Ahmed K, et al. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol. 2008;48:79–106.PubMedCrossRefGoogle Scholar
  25. 25.
    Wanders D, Judd RL. Future of GPR109A agonists in the treatment of dyslipidemia. Diabetes Obes Metabol. 2011.Google Scholar
  26. 26.
    Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol. 2004;67:411–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Lukasova M, Malaval C, Gille A, et al. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest. 2011;121:1163–73.PubMedCrossRefGoogle Scholar
  28. 28.
    • Ganji SH, Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009;202:68–75. This work reports potential pleiotropic mechanisms of niacin on the atherosclerosis process. PubMedCrossRefGoogle Scholar
  29. 29.
    Benjo AM, Maranhao RC, Coimbra SR, et al. Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment. Atherosclerosis. 2006;187:116–22.PubMedCrossRefGoogle Scholar
  30. 30.
    Hamilton SJ, Chew GT, Davis TM, et al. Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients. Diab Vasc Dis Res. 2010;7:296–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Warnholtz A, Wild P, Ostad MA, et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis. 2009;204:216–21.PubMedCrossRefGoogle Scholar
  32. 32.
    Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360–81.Google Scholar
  33. 33.
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245–55.PubMedCrossRefGoogle Scholar
  34. 34.
    Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289–98.PubMedCrossRefGoogle Scholar
  35. 35.
    Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583–92.PubMedCrossRefGoogle Scholar
  36. 36.
    Whitney EJ, Krasuski RA, Personius BE, et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med. 2005;142:95–104.PubMedGoogle Scholar
  37. 37.
    • The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J. 2011;161:538–43. This work describes the methods of the AIM-HIGH trial. Google Scholar
  38. 38.
    NHLBI Press Release on Stopping AIM-HIGH Trial. Available at http://public.nhlbi.nih.gov/newsroom/home/GetPressRelease.aspx?id=2792. Accessed June 5, 2011.
  39. 39.
    Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47:1097–104.PubMedCrossRefGoogle Scholar
  40. 40.
    Bays H, Shah A, Dong Q, et al. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. Int J Clin Pract. 2011;65:436–45.PubMedCrossRefGoogle Scholar
  41. 41.
    Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62:1959–70.PubMedCrossRefGoogle Scholar
  42. 42.
    Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol. 2009;104:74–81.PubMedCrossRefGoogle Scholar
  43. 43.
    McKenney J, Bays H, Koren M, et al. Safety of extended-release niacin/laropiprant in patients with dyslipidemia. J Clin Lipidol. 2010;4:105–12.PubMedCrossRefGoogle Scholar
  44. 44.
    Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol. 2008;101:625–30.PubMedCrossRefGoogle Scholar
  45. 45.
    Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102:1082–5.PubMedGoogle Scholar
  46. 46.
    • Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–28. This work reports two LPA genetic variants that were strongly and independently associated with both an increased level of Lp(a) lipoprotein and an increased risk of coronary disease, supporting a causal and genetic role for Lp(a) and coronary artery disease. PubMedCrossRefGoogle Scholar
  47. 47.
    McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 2001;88:270–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:e50–e103.PubMedCrossRefGoogle Scholar
  49. 49.
    Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185–97.PubMedCrossRefGoogle Scholar
  50. 50.
    Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol. 1998;82:737–43.PubMedCrossRefGoogle Scholar
  51. 51.
    Karas RH, Kashyap ML, Knopp RH, et al. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs. 2008;8:69–81.PubMedCrossRefGoogle Scholar
  52. 52.
    Brinton EA, Kashyap ML, Vo AN, et al. Niacin extended-release therapy in Phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis. Am J Cardiovasc Drugs. 2011;11:179–87.PubMedCrossRefGoogle Scholar
  53. 53.
    Keenan JM, Fontaine PL, Wenz JB, et al. Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991;151:1424–32.PubMedCrossRefGoogle Scholar
  54. 54.
    Keenan JM, Bae CY, Fontaine PL, et al. Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin. J Am Geriatr Soc. 1992;40:12–8.PubMedGoogle Scholar
  55. 55.
    McKenney JM, Proctor JD, Harris S, et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271:672–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Norris RB. “Flush-free niacin”: dietary supplement may be “benefit-free”. Prev Cardiol. 2006;9:64–5.PubMedCrossRefGoogle Scholar
  57. 57.
    Ziliotto GR, Lamberti G, Wagner A, et al. Comparative studies of the response of normolipemic and dyslipemic aged subjects to 2 forms of delayed-action nicotinic acid polyesters. Pentaerythrotol tetranicotinate and inositol hexanicotinate. Results of a controlled cross-over trial. Arch Sci Med Torino. 1977;134:359–94.PubMedGoogle Scholar
  58. 58.
    Benyo Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest. 2005;115:3634–40.PubMedCrossRefGoogle Scholar
  59. 59.
    Benyo Z, Gille A, Bennett CL, et al. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol. 2006;70:1844–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Kamal-Bahl S, Watson DJ, Ambegaonkar BM. Patients’ experiences of niacin-induced flushing in clinical practice: a structured telephone interview. Clin Ther. 2009;31:130–40.PubMedCrossRefGoogle Scholar
  61. 61.
    Goldberg A, Alagona Jr P, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 2000;85:1100–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Taylor AJ, Stanek EJ. Flushing and the HDL-C response to extended-release niacin. J Clin Lipidol. 2008;2:285–8.PubMedCrossRefGoogle Scholar
  63. 63.
    Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;264:723–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Taylor AJ, Zhu D, Sullenberger LE, et al. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. Vasc Health Risk Manag. 2007;3:159–64.PubMedGoogle Scholar
  65. 65.
    Vittone F, Chait A, Morse JS, et al. Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS). J Clin Lipidol. 2007;1:203–10.PubMedCrossRefGoogle Scholar
  66. 66.
    • Linke A, Sonnabend M, Fasshauer M, et al. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis. 2009;205:207–13. This work reports the favorable impact of niacin extended-release on lipid parameters, adipocyte size, and insulin sensitivity in patients with impaired glucose tolerance. PubMedCrossRefGoogle Scholar
  67. 67.
    Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc. 2008;83:470–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Gray DR, Morgan T, Chretien SD, et al. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 1994;121:252–8.PubMedGoogle Scholar
  69. 69.
    Alsheikh-Ali AA, Karas RH. The safety of niacin in the US Food and Drug Administration adverse event reporting database. Am J Cardiol. 2008;101:9B–13B.PubMedCrossRefGoogle Scholar
  70. 70.
    Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol. 2008;101:1428–36.PubMedCrossRefGoogle Scholar
  71. 71.
    Zhao XQ, Morse JS, Dowdy AA, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol. 2004;93:307–12.PubMedCrossRefGoogle Scholar
  72. 72.
    Jacobson TA. A “hot” topic in dyslipidemia management–“how to beat a flush”: optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Mayo Clin Proc. 2010;85:365–79.PubMedCrossRefGoogle Scholar
  73. 73.
    Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract. 2006;60:707–15.PubMedCrossRefGoogle Scholar
  74. 74.
    Whelan AM, Price SO, Fowler SF, et al. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract. 1992;34:165–8.PubMedGoogle Scholar
  75. 75.
    Wilkin JK, Wilkin O, Kapp R, et al. Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther. 1982;31:478–82.PubMedCrossRefGoogle Scholar
  76. 76.
    Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. Available at http://clinicaltrials.gov/ct2/show/NCT00461630. Accessed June 5, 2011.
  77. 77.
    Shen HC, Colletti SL. Novel patent publications on high-affinity nicotinic acid receptor agonists. Expert Opin Ther Pat. 2009;19:957–67.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2011

Authors and Affiliations

  • Todd C. Villines
    • 1
    • 4
  • Andrew S. Kim
    • 1
  • Rosco S. Gore
    • 1
  • Allen J. Taylor
    • 2
    • 3
  1. 1.Cardiology Service, Department of MedicineWalter Reed National Military Medical CenterBethesdaUSA
  2. 2.Washington Hospital CenterWashingtonUSA
  3. 3.Georgetown University School of MedicineWashingtonUSA
  4. 4.Uniformed Services University School of MedicineBethesdaUSA

Personalised recommendations